Memantine Dr. Reddy’s

Memantine, the active ingredient in Memantine Dr. Reddy’s, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults, helping to mitigate cognitive decline associated with the condition.

GNH USA supplies Memantine Dr. Reddy’s as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent supply chains and regulatory support across multiple markets.

Memantine is used in the management of Alzheimer’s disease, targeting glutamatergic excitotoxic pathways that contribute to neurodegeneration.

- Alzheimer's disease (mild to moderate): improves cognition and daily functioning in patients with early‑stage disease. - Alzheimer's disease (moderate to severe): helps maintain functional abilities and may slow progression in later stages. - Alzheimer's disease (maintenance therapy): used as long‑term treatment to sustain cognitive benefits after initial response.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating memantine therapy, consider the following precautions to ensure safe use.

- Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use cautiously in patients with uncontrolled hypertension or heart failure. - Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors. - Pregnancy: safety not established; weigh potential benefits against unknown risks. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuropsychiatric effects. - Ketamine: combined CNS depression and heightened psychotomimetic reactions. - Other NMDA antagonists (e.g., dextromethorphan): risk of excessive inhibition of glutamate signaling.

Moderate Interactions (Monitor Closely): - Antihypertensives: memantine may enhance blood pressure‑lowering effects. - CNS depressants (e.g., benzodiazepines): increased sedation or dizziness. - Diuretics: potential alteration of electrolyte balance affecting memantine levels.